Q4 Earnings Estimate for argenx Issued By William Blair

argenx SE (NASDAQ:ARGX) – Stock analysts at William Blair issued their Q4 2026 earnings per share estimates for argenx in a report released on Monday, March 17th. William Blair analyst M. Minter forecasts that the company will post earnings of $7.29 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share.

Several other research firms have also recently commented on ARGX. Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research note on Wednesday, March 12th. Guggenheim boosted their target price on argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Citigroup reissued an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Robert W. Baird boosted their target price on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 4th. Finally, Sanford C. Bernstein raised argenx from a “market perform” rating to an “outperform” rating in a research report on Monday. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Price Performance

ARGX opened at $611.18 on Tuesday. argenx has a 12 month low of $349.86 and a 12 month high of $678.21. The stock has a market capitalization of $37.14 billion, a price-to-earnings ratio of -694.52 and a beta of 0.59. The business has a fifty day moving average price of $636.83 and a 200 day moving average price of $598.22.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million.

Institutional Trading of argenx

Several institutional investors and hedge funds have recently made changes to their positions in ARGX. FMR LLC raised its stake in argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in argenx during the 3rd quarter valued at approximately $88,339,000. Point72 Asset Management L.P. purchased a new stake in argenx during the 4th quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC raised its stake in argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after acquiring an additional 143,834 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in argenx by 184.7% during the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company’s stock valued at $117,805,000 after acquiring an additional 124,271 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.